Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.
about
Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitorsGenomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.Patients' preferences: a discrete-choice experiment for treatment of non-small-cell lung cancerRisk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.The quest to overcome resistance to EGFR-targeted therapies in cancer.Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutationHigh efficacy of gefitinib in the treatment of EGFR mutation-positive advanced non-small cell lung adenocarcinoma: A case report.Development of the rat model of lapatinib-induced diarrhoea.Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy.Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patientsAdherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review.Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis.Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectivenessGenetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patientsLong-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report.The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report.Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancerTyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Targeting the epidermal growth factor receptor in solid tumors: focus on safety.Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.HOX genes: potential candidates for the progression of laryngeal squamous cell carcinoma.Minocycline Improves the Efficacy of EGFR Inhibitor Therapy: A Hypothesis.Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study.High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors.Cutaneous Toxicities of Molecular Targeted Therapies.Preventing or treating anti-EGFR related skin rash with antibiotics?Turn on the TORCH before treat your patients: a lesson from a first line study in advanced NSCLC.Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.Targeted Therapy for Medullary Thyroid Cancer: A Review.
P2860
Q26781472-913E1295-B208-444B-8A4E-88B6D06542D1Q27853189-612432E3-E724-4926-B4DB-349D8A3391A8Q28396145-11E738FD-7E12-43E3-9388-B503DB09DE74Q30248499-940765C8-DEC8-49C4-A726-4881A4069274Q33725976-B1C61313-4754-439C-96AB-E4B42A28B89EQ33955857-F5B19978-125C-43DE-A283-20B02B81DF41Q33968079-E2A91683-1976-43A6-A511-21BA3F6A2301Q33999288-56BC2067-F61B-4A23-8CD6-AF7DAA0C6359Q34774866-26BB8E2B-82A5-4F8C-B350-CCB9D243748AQ35478632-AE162963-E118-49D6-B2E3-4B114E01EE80Q35749286-9D7F69B8-512F-4F25-89D6-0D7B92199DA0Q35870274-3518A7F4-AC04-4CF4-BF84-4F1D856FC6E8Q36026706-7AEBA8AA-24F9-45A1-B807-8449619B220CQ36205327-E1203EC2-4DFC-4D49-B5A1-862BF74BD998Q36234132-B9F97FFA-6838-4C91-B355-BA7B8111DCE0Q36700258-E01C068E-1FCD-4171-9014-F856FBB99296Q36778198-FEA5FC14-8E4B-4CEE-87DE-E8E0AF7D64E1Q36797076-9B4EE9FF-7097-4F9F-A89D-5AFC1D6812F1Q37226025-88F5D652-9E9A-4448-B1D4-645CD410FA3BQ37689074-A2A06B3A-973F-4050-9A6B-C02BAE5E495BQ37693919-8AD3DC41-0BFB-4F69-A46B-287F70C77CC0Q38101885-B2AB9575-7610-4777-BE27-1280AFF09C80Q38190857-23082C91-975D-4902-8D3D-2A5575B38FE9Q38200654-70EFCF0C-731C-4A15-990D-96AAEA4A1C93Q38222703-0D391A13-8D0D-4F25-8E50-C3D66E86C8C6Q38289406-2E2D8C13-420D-4000-BF65-83B56ECDC885Q38891976-BF31775F-D5B0-450D-B520-600053722E39Q38937228-FBFE1773-853E-43F0-AD2D-B06A8550EF7BQ39361446-F13761C0-5871-4F7E-B8ED-76C63AA2B02DQ40456709-0F170441-B871-4B80-8426-690467771170Q40985350-938095A1-E57C-4ED3-9188-8E2464E743BEQ41289945-88554AB4-F3AA-48BD-B317-BC41B51B523EQ41541640-DEDF0F8E-4E92-4B46-BF03-9342B3B328E2Q42398733-1CCFD76E-0245-48D6-8415-132125F17B9AQ43195725-6266A082-5A08-4998-AA06-AEC358075552Q46296117-37AF4585-CEAC-4494-B2C6-B9C475039AA0Q47969048-3994C4F1-A146-42C6-8750-5CC6D90EA159Q48126437-74223879-1E85-4985-B230-03A27E2C1B17Q48327823-168EFD5C-30BA-4128-ABC4-54752E997068Q49328959-95E86061-DFAA-47F7-81FB-BE11D98E5384
P2860
Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Relationship between skin rash ...... ed meta-analysis of 24 trials.
@en
type
label
Relationship between skin rash ...... ed meta-analysis of 24 trials.
@en
prefLabel
Relationship between skin rash ...... ed meta-analysis of 24 trials.
@en
P2093
P1433
P1476
Relationship between skin rash ...... ed meta-analysis of 24 trials.
@en
P2093
Fausto Petrelli
Karen Borgonovo
Mary Cabiddu
Sandro Barni
Veronica Lonati
P356
10.1016/J.LUNGCAN.2012.06.009
P577
2012-07-12T00:00:00Z